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Abstract Eotaxin is a potent and selective CC chemokine for
eosinophils and basophils. We established several monoclonal
antibodies (Mabs) allowing the neutralization and measurement
of human eotaxin. Using the Mabs as probes, we demonstrated
that normal eosinophils contained intracellular granule-asso-
ciated eotaxin. Quantification of cell-associated eotaxin in
different leukocyte subsets revealed that it was principally
expressed in eosinophils. Finally, we showed that normal
eosinophils released eotaxin upon stimulation with either of two
secretagogues, C5a or ionomycin. These findings raise the
possibility that eosinophil-derived eotaxin contributes to the
local accumulation of eosinophils at the site of inflammation.
z 1998 Federation of European Biochemical Societies.
Key words: Eotaxin; Eosinophil ; Chemokine
1. Introduction
Eosinophil in¢ltration is a fundamental trait of parasitic
infections and allergic diseases [1]. Through the release of
diverse toxic mediators, activated eosinophils contribute to
parasite killing and associated tissue damage [2]. In addition,
the recent demonstration that eosinophils may release various
cytokines suggests that these cells play a regulatory role in
in£ammation associated with allergic disorders [3^15]. Indeed,
there is evidence that these cytokines may regulate the main-
tenance and progression of allergic in£ammation through au-
tocrine and/or paracrine mechanisms.
Although the processes involved in local eosinophilia are
not fully understood, accumulating evidence indicates that
the recruitment and activation of leukocytes in in£ammatory
processes are regulated by a large number of CXC and CC
chemokines [16,17]. As a speci¢c CC chemokine for eosino-
phils, eotaxin was puri¢ed from the bronchoalveolar lavage
£uid of a guinea pig model of allergic lung in£ammation by
Williams and colleagues [18] in 1993. In animals, eotaxin in-
duces local accumulation of eosinophils in synergy with inter-
leukin (IL)-5 [19^21]. In humans, increased expression of eo-
taxin was observed in the bronchoalveolar lavage £uid and
airway biopsies of asthmatic patients [22,23].
In the present study, we established several monoclonal
antibodies (Mabs) to human eotaxin and developed a sensitive
enzyme-linked immunosorbent assay (ELISA) system for the
quanti¢cation of eotaxin. We demonstrated the localization
and storage of eotaxin in normal eosinophils, and the release
of eosinophil-associated eotaxin upon stimulation with either
C5a or ionomycin.
2. Materials and methods
2.1. Reagents
Recombinant human macrophage chemoattractant protein (MCP)-
1, MCP-2, MCP-3, MCP-4, human macrophage in£ammatory protein
(MIP)-1K, eotaxin-2 and RANTES were purchased from PeproTech
EC (London, UK). The production and puri¢cation of recombinant
human eotaxin were performed as described previously [24]. Natural
eotaxin-K, -L and -Q were puri¢ed from the supernatant of IL-4-stimu-
lated dermal ¢broblasts as described previously [25]. Bovine serum
albumin (BSA), and Tween 20 were obtained from Sigma (St. Louis,
MO, USA).
2.2. Hybridoma production
BALB/c mice were injected subcutaneously with 2 Wg of recombi-
nant human eotaxin emulsi¢ed in complete Freund’s adjuvant (Difco,
Detroit, MI, USA). Additional injections of 1 Wg of recombinant
human eotaxin emulsi¢ed in incomplete Freund’s adjuvant (Difco)
were administered three more times at 1^2-week intervals. Three
days before fusion, mice received an intravenous injection of 1 Wg
of recombinant eotaxin. Spleen cells were isolated and fused with
P3U1 myeloma cells using 50% (w/v) polyethylene glycol solution
(Sigma). Hybridomas were selected in hypoxanthine-aminopterin-thy-
midine medium supplemented with 10% fetal calf serum (Dainippon,
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Fig. 1. Inhibition of eosinophil chemotaxis by Mab 164.44. After
preincubation of recombinant human eotaxin with various concen-
trations of Mab 164.44 for 1 h, eotaxin-induced eosinophil chemo-
taxis was performed using 96-well modi¢ed Boyden microchemo-
taxis chambers, as described in Section 2.
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Osaka, Japan) and 5% BriClone (BioResearch Ireland, Dublin, Ire-
land). Hybridomas were screened by ELISA, and positive hybridomas
were subcloned by limiting dilution. For screening of anti-eotaxin
antibody-producing hybridomas, 96-well microplates (Maxisorp,
Nunc, Denmark) were coated with 75 Wl per well of eotaxin (5 Wg/
ml in bicarbonate bu¡er, pH 9.0) overnight. The plates were washed
with PBS containing 0.1% Tween 20. Hybridoma supernatants were
added and incubated at 4‡C overnight. The plates were washed, and
bound antibodies were detected with horseradish peroxidase (HRPO)-
labeled anti-mouse Ig antibody (Jackson ImmunoResearch, West
Grove, PA, USA) for 3 h. After additional washing, the reaction
was developed using a TMB microwell peroxidase substrate system
(Kirkengaard and Perry, Gaithersburg, MD, USA). Absorbance was
measured using an ELISA reader (Bio-Rad, Melville, NY, USA) at
450 nm.
2.3. Antibody isotyping and puri¢cation
The class and subclass of monoclonal antibodies were determined
by ELISA. Ascites was generated by injecting 106 hybridoma cells
into the peritoneal cavity of pristane-primed BALB/c mice. The ascites
was clari¢ed by centrifugation, and the Mab was puri¢ed by using a
protein A a⁄nity chromatography kit (Bio-Rad) according to the
manufacturer’s instructions.
2.4. ELISA for eotaxin
A double-sandwich ELISA for measurement of human eotaxin was
FEBS 20625 3-9-98 Cyaan Magenta Geel Zwart
Fig. 2. Light micrographs (U400) of peripheral blood eosinophils stained with normal mouse IgG1 (A) or monoclonal anti-eotaxin antibody
(Mab 174.4) (B) and counterstained with Myer’s hematoxylin.
Table 1
Measurement of cell-associated eotaxin in freshly isolated peripheral
blood eosinophils, PMNs and MNCs from normal individuals
Cell Eotaxin (pg/106 cells)
Eosinophils (n = 5) 19.53 þ 3.53a
PMNs (n = 4) 0.80 þ 0.83
MNCs (n = 4) 2.09 þ 0.77
aMean þ S.D.; eotaxin was determined by ELISA after cell lysis.
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developed by using two Mabs. ELISA microtiter plates (Covalink
NH, F8 Modules, Nunc) were coated with Mab 164.44 by using a
crosslinking reagent, disuccinimidyl suberate (Pierce, Rockford, IL,
USA). Samples were added to Mab-coated plates, which were washed
and incubated with HRPO conjugated-Mab 174.4 FabP (HRPO-con-
jugated FabP was kindly prepared by Dr. A. Morita, ShionogipCo.,
Osaka, Japan). The plates were developed with the TMB microwell
peroxidase substrate system, and the reactions were stopped with 2 N
H2SO4. Absorbance was measured at 450 nm, and a standard curve
was generated by using recombinant eotaxin for each assay.
2.5. Cell culture
Eosinophils, polymorphonuclear cells (PMNs) and mononuclear
cells (MNCs) were isolated from the peripheral blood of healthy in-
dividuals. The purity of eosinophils was more than 95%. Highly pu-
ri¢ed eosinophils were stimulated with either cytochalasin B (CB;
5 Wg/ml; Sigma) plus C5a (100 nM; Sigma) or ionomycin (1 WM;
Calbiochem-Behring, La Jolla, CA, USA) in PIPES bu¡er (pH 7.4)
containing 0.03% human serum albumin for 60 min at 37‡C as de-
scribed previously [26]. Supernatants were harvested by centrifuga-
tion. Cell lysates were prepared by addition of 0.5% Nonidet P-40
and stored at 380‡C.
2.6. Eosinophil chemotaxis assay
The neutralizing activity of the Mabs against human eotaxin was
tested by the human eosinophil chemotaxis assay. The assay was
performed using an assembly consisting of a 96-well modi¢ed Boyden
microchemotaxis chamber and a polycarbonate ¢lter membrane (pore
size 5 Wm; Nucleopore, Pleasanton, CA, USA), as previously de-
scribed [27].
2.7. Immunocytochemistry
Smears of eosinophils were prepared with a cytocentrifuge onto
poly-L-lysine-coated glass slides. Cells were ¢xed with 4% paraformal-
dehyde in PBS, pH 7.4, for 20 min and treated with 0.1% trypsin. The
slides were blocked with Tris-bu¡ered saline, pH 7.6, containing 2%
BSA and 5% normal goat serum, for 2 h at room temperature. To
detect intracellular eotaxin, the cells were incubated with Mab 174.4
overnight and stained with a commercially available biotin-streptavi-
din system (LSAB-AP Kit, DAKO, Carpenteria, CA, USA). Isotype-
matched mouse IgG was used as negative control. Cells were also
counterstained with Myer’s hematoxylin.
Immunoelectron microscopy was performed as described previ-
ously, with some modi¢cations [28,29]. We used JB-4 resin (Polyscien-
ces, Warrington, PA, USA) for indirect immunoelectron microscopic
labeling using a postembedding procedure. Eosinophils were ¢xed
with a 4% paraformaldehyde, 0.75% glutaraldehyde, 1 mM CaCl2,
0.1 M phosphate-bu¡ered solution. The sections were incubated
with either Mab 174.4 or isotype-matched mouse IgG for 12 h at
room temperature. They were then labeled with gold particle-conju-
gated anti-mouse IgG(H+L) antibody (10 nm; GMHL10, British Bio-
Cell International, Cardi¡, UK). Finally, the sections were stained
with 1% aqueous uranyl acetate followed by a Reynolds’ lead citrate
solution. The electron microscope used was a Hitachi 1200-EX at an
acceleration voltage of 100 kV.
3. Results
Five Mabs were produced by immunizing mice with re-
combinant eotaxin. Two of the Mabs, designated Mab
164.44 (IgG2a) and Mab 174.4 (IgG1), were fully character-
ized in terms of their antigen speci¢city and neutralizing ac-
tivity. Their speci¢city was con¢rmed by direct-binding ELI-
SA: they did not react with either MCP-1, MCP-2, MCP-3,
MCP-4, MIP-1K, IL-8 or RANTES (data not shown). Fur-
thermore, Mab 164.44 antagonized eotaxin-induced eosino-
phil chemotactic activity: 50% inhibition was obtained at a
molecular ratio (Mab/eotaxin) of approximately 1.0 (Fig. 1).
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Fig. 3. Immunoelectron micrographs of human eosinophils labeled
with normal mouse IgG1 or monoclonal anti-eotaxin antibody
(Mab 174.4) followed by 10 nm gold particle-conjugated anti-mouse
IgG(H+L). Negative-control labeling of speci¢c granules (SG) in an
eosinophil using normal mouse IgG1 substituted for the primary
antibody (A) or with Mab 174.4 (B). C: central core of SG; M:
matrix of SG; Nu: nucleus.
Fig. 4. Detection of recombinant and natural eotaxin by ELISA.
Recombinant and dermal ¢broblast-derived eotaxin (eotaxin-K, -L
and -Q) were measured by sandwich ELISA using two Mabs (Mab
164.44 and Mab 174.4), as described in Section 2.
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Similar neutralizing activity was observed with Mab 174.4
(data not shown). To determine the presence of eotaxin in
eosinophils, cells were puri¢ed from ¢ve non-allergic donors
and reacted with Mab 174.4. As illustrated in Fig. 2, eosino-
phils were intensely stained with Mab 174.4. Immunoelectron
microscopic analysis further demonstrated the intracellular
localization of eotaxin to speci¢c granules with the cytoplasm
of eosinophils (Fig. 3).
In order to quantify the protein levels of human eotaxin, an
ELISA system was developed by using Mab 164.44 and Mab
174.4. As shown in Fig. 4, the ELISA system was able to
recognize not only recombinant eotaxin but also natural eo-
taxin-K, -L and -Q puri¢ed from supernatants of IL-4-stimu-
lated dermal ¢broblasts [25]. The detectable range of eotaxin
was 0.6^60 pM (approximately 5^500 pg/ml). There was no
crossreaction with eotaxin-2, MCP-1, -2, -3, -4, RANTES,
MIP-1K, pulmonary and activation-regulated chemokine
(PARC), thymus and activation-regulated chemokine
(TARC), liver and activation-regulated chemokine (LARC),
lymphotactin (SCM-1), fractalkine or IL-8 (data not shown).
Eosinophils, PMNs and MNCs were separated from healthy
donors, and cell-associated eotaxin was measured with this
ELISA system. As shown in Table 1, signi¢cant amounts of
eotaxin were detected in peripheral eosinophils compared to
PMNs and MNCs.
Since immunoelectron microscopic examination revealed
that eotaxin was associated with speci¢c granules in eosino-
phils, we next determined whether eotaxin was liberated dur-
ing the process of degranulation. Puri¢ed eosinophils were
stimulated with an established secretagogue, C5a, for 60
min. As shown in Fig. 5, the eosinophils released approxi-
mately 28.3% (range 22.6^37.2%) of their total intracellular
eotaxin in response to C5a. Stimulation with a non-speci¢c
secretagogue, ionomycin, also resulted in the release of gran-
ule-associated eotaxin (Fig. 5, donor 4).
4. Discussion
Eotaxin is the most potent known chemoattractant for both
eosinophils and basophils [27]. A high-a⁄nity receptor for
eotaxin, designated CC chemokine receptor (CCR)3, was
identi¢ed on eosinophils [24,30], basophils [31] and T-cells
of the Th2 subset [32,33], all of which are predominant cells
at the sites of ongoing allergic diseases. Other CCR3 ligands
[34,35], such as RANTES and MCP-3, are able to bind to
other types of CCR [36], and they are thereby active on var-
ious cell types. In contrast, eotaxin binds only to CCR3 and
displays a selective chemotactic e¡ect on eosinophils and ba-
sophils.
The expression of human eotaxin mRNA and/or protein
was reported in various types of cells, including ¢broblasts
[25,37], epithelial cells [38], endothelial cells [39], T cells and
macrophages [40]. Studies on biopsy specimens from the
upper and lower airways of patients with allergic diseases
revealed the expression of eotaxin protein in eosinophils in-
¢ltrating the in£ammatory sites [22,23]. Using speci¢c Mabs
and a sensitive ELISA system, we here provide several lines of
evidence that peripheral eosinophils of non-allergic individu-
als constitutively express eotaxin. Immunohistochemical ex-
periments demonstrated the expression of eotaxin protein at
the single-cell level. Quanti¢cation of cell-associated eotaxin
revealed that eosinophils possess greater amounts of eotaxin
compared to other types of cells in the peripheral blood. Most
importantly, eotaxin was localized in the matrix of crystalloid
granules of eosinophils and was released upon eosinophilic
activation.
Freshly isolated eosinophils store several cytokines, includ-
ing IL-4 [4,18,41], GM-CSF [14], IL-8 [11,13] and RANTES
[4]. These preformed cytokines are liberated in response to
appropriate stimuli and may contribute to allergic in£amma-
tion through autocrine and/or paracrine mechanisms. At
present, the physiological signi¢cance of eosinophil-derived
eotaxin is not fully understood. The amount of eotaxin in
eosinophils (V20 pg/106 cells) was below the physiological
relevant range (i.e. more than 10 ng/ml of eotaxin was re-
quired for chemotaxis of eosinophils in vitro [27]), indicating
that eosinophils do not represent a major source of this mol-
ecule. We think that one of the major sources of eotaxin is
¢broblasts, because we determined that IL-4- plus TNF-
K-stimulated dermal ¢broblasts released eotaxin in the order
of 100 ng/ml into the culture supernatant (unpublished obser-
vation). However, the release of eotaxin from eosinophils may
represent the autocrine and/or paracrine pathway of local eo-
sinophil accumulation in in£ammatory tissues. Although the
role of eotaxin inside eosinophils is still unclear, further stud-
ies are necessary for the understanding of the presence of
eotaxin in the cells.
In summary, we have demonstrated localization and stor-
age of eotaxin in normal human eosinophils. We are currently
analyzing preformed eotaxin in eosinophils of patients with
allergic diseases. Our results suggest that eosinophils are an
important cellular source of eotaxin.
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